SBRT
Clinical trials for SBRT explained in plain language.
Never miss a new study
Get alerted when new SBRT trials appear
Sign up with your email to follow new studies for SBRT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a One-Week radiation course match four weeks for prostate cancer?
Disease control Not yet recruitingResearchers are testing whether a five-fraction course of stereotactic body radiotherapy (SBRT) works as well as the standard 20-fraction radiotherapy for men who need radiation after prostate cancer surgery. The trial enrolls 206 adults and randomly assigns them to either the sh…
Matched conditions: SBRT
Phase 3 • Sponsor: Robert Förster • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Can zapping residual lung cancer spots extend remission?
Disease control Not yet recruitingResearchers are testing whether adding focused radiation to the few remaining cancer spots helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their disease getting worse. Participants first receive a third-generation EGFR-targeted drug plus plat…
Matched conditions: SBRT
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New combo therapy takes aim at Hard-to-Treat salivary gland cancer
Disease control Not yet recruitingThis phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease …
Matched conditions: SBRT
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New triple combo aims to tackle Hard-to-Treat liver cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow …
Matched conditions: SBRT
Phase 2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC